摘要 :
Evaluation of Silver Coated Hemostatic Dressing to Control Hemorrhage in a Porcine Model of Lethal Vascular InjuryThe aim of the study. An ideal hemostatic dressing that would control bleeding and protect the wound from further co...
展开
Evaluation of Silver Coated Hemostatic Dressing to Control Hemorrhage in a Porcine Model of Lethal Vascular InjuryThe aim of the study. An ideal hemostatic dressing that would control bleeding and protect the wound from further contamination is still being sought for combat casualty care. The new SilverLeaf? (SL) bandage was made of material containing active hemostatic property and possible antimicrobial property from silver coating. This study was conducted to compare and ascertain the hemostatic properties of SL and compare it with known hemostatic dressings: Combat Gauze? (CG) and WoundStat? (WS) in a swine model with punch, vascular injury.Material and methods. Three hemostatic dressings were evaluated in anesthetized Yorkshire swine hemorrhaged for 45 sec in a femoral arterial puncture model. The hemostatic dressings SL, CG, or WS were applied on an actively bleeding wound, followed by 5 minutes of compression at 200 mm Hg. The pressure was then released to baseline and skin closed with towel clamps. After 15 minutes, 500 ml of (Hextend) resuscitation fluid infused over a period of 30 minutes. The animal's vital signs were monitored for the 3-hour experiment period. Primary outcomes documented were incidence of bleeding after application of the dressing, restoration of MAP and rate of survival.Results. The pre-treatment blood loss for WS was 375.66 ml (16.49%), SL 282.08 ml (12.15%) and CG 307.24 ml (12.68%) and was comparable between groups (p>0.56). The post-treatment blood loss for WS was 286.05 ml (10.65%), SL 386.81 ml (16.92%), and CG 525.76 ml (21.52%). There was no significant difference in post-treatment blood loss (p>0.37) between groups. The Mean Arterial Pressure (MAP) did not significantly differ between the groups at all time points compared. The SL and CG had comparable MAPS during the first hour. The SL had a slight advantage, but didn't reach statistical significance. This suggests that all the bandages were comparable. The two time points at which the post-treatment bleeding occurred in the three groups after the release of manual compression and after restoration of blood pressure. The post-treatment re-bleeding rates were 22.22% (2/9) for WS and SL, 44.44% (4/9) for CG. The survival rates were 100% for WS, 88.89% for SL, and 77.78% for CG.Conclusion. The findings indicate that SilverLeaf, WoundStat and Combat Gauze were comparable in controlling bleeding, preventing re-bleeding, maintenance of mean arterial pressure and improving survival following treatment.
收起
摘要 :
BACKGROUND: The recently developed the Src and Abelson (Abl) kinase inhibitor dasatinib has antitumor effects in epithelial and mesenchymal tumors. Preclinical data have indicated that dasatinib is metabolized primarily through cy...
展开
BACKGROUND: The recently developed the Src and Abelson (Abl) kinase inhibitor dasatinib has antitumor effects in epithelial and mesenchymal tumors. Preclinical data have indicated that dasatinib is metabolized primarily through cytochrome P450 3A4 (CYP3A4) and may cause QT prolongation. In light of its improved tolerability, the authors were interested in the safety of a once-daily dasatinib regimen. METHODS: The authors conducted a phase 1 trial of dasatinib in 29 patients with advanced solid tumors. Segment 1 of the trial was short term and sequential and was designed to determine whether the coadministration of the potent CYP3A4 inhibitor ketoconazole had an effect on the pharmacokinetics of dasatinib. Segment 2 was designed to evaluate the safety of dasatinib as dosing was increased. QT intervals were monitored closely in both segments. Efficacy was assessed in Segment 2 using both positron emission tomography and computed tomography. RESULTS: Hematologic toxicities were markedly less than those observed in patients with leukemia, whereas nonhematologic toxicities were similar. The authors determined that the maximum recommended dose was 180 mg once daily based on the incidence of pleural effusion. Coadministration of ketoconazole led to a marked increase in dasatinib exposure, which was correlated with an increase in corrected QT (QTc) values of approximately 6 msec. No adverse cardiac events were observed. CONCLUSIONS: The dose-limiting toxic effect for dasatinib was pleural effusion. The pharmacokinetic and cardiac studies indicated that coadministration of dasatinib with potent CYP3A4 inhibitors or agents that prolong the QTc interval should be avoided if possible. Close monitoring for toxicity and dose reduction should be considered if the coadministration of such agents cannot be avoided.
收起
摘要 :
BACKGROUND: The recently developed the Src and Abelson (Abl) kinase inhibitor dasatinib has antitumor effects in epithelial and mesenchymal tumors. Preclinical data have indicated that dasatinib is metabolized primarily through cy...
展开
BACKGROUND: The recently developed the Src and Abelson (Abl) kinase inhibitor dasatinib has antitumor effects in epithelial and mesenchymal tumors. Preclinical data have indicated that dasatinib is metabolized primarily through cytochrome P450 3A4 (CYP3A4) and may cause QT prolongation. In light of its improved tolerability, the authors were interested in the safety of a once-daily dasatinib regimen. METHODS: The authors conducted a phase 1 trial of dasatinib in 29 patients with advanced solid tumors. Segment 1 of the trial was short term and sequential and was designed to determine whether the coadministration of the potent CYP3A4 inhibitor ketoconazole had an effect on the pharmacokinetics of dasatinib. Segment 2 was designed to evaluate the safety of dasatinib as dosing was increased. QT intervals were monitored closely in both segments. Efficacy was assessed in Segment 2 using both positron emission tomography and computed tomography. RESULTS: Hematologic toxicities were markedly less than those observed in patients with leukemia, whereas nonhematologic toxicities were similar. The authors determined that the maximum recommended dose was 180 mg once daily based on the incidence of pleural effusion. Coadministration of ketoconazole led to a marked increase in dasatinib exposure, which was correlated with an increase in corrected QT (QTc) values of approximately 6 msec. No adverse cardiac events were observed. CONCLUSIONS: The dose-limiting toxic effect for dasatinib was pleural effusion. The pharmacokinetic and cardiac studies indicated that coadministration of dasatinib with potent CYP3A4 inhibitors or agents that prolong the QTc interval should be avoided if possible. Close monitoring for toxicity and dose reduction should be considered if the coadministration of such agents cannot be avoided.
收起
摘要 :
Background: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. Methods: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m2 IV, and c...
展开
Background: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. Methods: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m2 IV, and carboplatin AUC = 6 IV every 21 days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21 days until progressive disease or unacceptable toxicity. Results: 29 of 66 patients (44%) had objective responses. The median TTP was 6 months; median overall survival (OS) was 17 months. Panitumumab increased treatment-related toxicity, notably skin rash. Conclusions: The addition of panitumumab increased toxicity, and had no discernible impact on efficacy.
收起
摘要 :
Signature molecules derived from Listeria monocytogenes, Bacillus thuringiensis, and Salmonella Typhimurium were detected directly on food substrates (mega) by coupling molecular beacon technology utilizing fluorescent resonance e...
展开
Signature molecules derived from Listeria monocytogenes, Bacillus thuringiensis, and Salmonella Typhimurium were detected directly on food substrates (mega) by coupling molecular beacon technology utilizing fluorescent resonance energy transfer (FRET), luminescent nanoscale semiconductor quantum dots, and nanoscale quenchers. We designed target DNA sequences for detecting hlyA, Bt cry1Ac, and invA genes from L. monocytogenes, B. thuringiensis and Salmonella Typhimurium, respectively, and prepared molecular beacons for specific targets for use in real-time monitoring. We successfully detected increased fluorescence in the presence of signature molecules at molecular beacon (MB) concentrations from 1.17 nM to 40 nM, depending upon system tested in (water, milk or plant leaves), respective target (hlyA, Bt cry1Ac, or invA) and genomic DNA target concentration (50–800 ng). We were able to detect bacterial genomic DNA derived from L. monocytogenes and Salmonella sp. in a food system, 2% milk ($>20$% of total volume). Furthermore, we infiltrated the Bt cry1Ac beacon in the presence of genomic DNA extracted from B. thuringiensis into Arabidopsis thaliana leaves and observed increased fluorescence in the presence of the target, indicating the ability to use these beacons in a plant system.
收起
摘要 :
JUDO TRAINING IS AN INTERMITTENT METABOLICALLY DEMANDING ACTIVITY THAT HAS HISTORICALLY BEEN CONNECTED TO PHYSICAL EDUCATION AND DEVELOPMENT. THE HEALTH IMPACT OF PRACTICING THIS OLYMPIC SPORT AND MARTIAL ART HIGHLIGHTS THE BENEFI...
展开
JUDO TRAINING IS AN INTERMITTENT METABOLICALLY DEMANDING ACTIVITY THAT HAS HISTORICALLY BEEN CONNECTED TO PHYSICAL EDUCATION AND DEVELOPMENT. THE HEALTH IMPACT OF PRACTICING THIS OLYMPIC SPORT AND MARTIAL ART HIGHLIGHTS THE BENEFITS OF COMBAT SPORTS FOR CHILDREN AND ADOLESCENTS. VARIOUS PHYSIOLOGICAL IMPROVEMENTS, INCLUDING THOSE IN THE AREAS OF BODY COMPOSITION, STRENGTH, AND ENDURANCE, AS WELL AS ENHANCED COGNITIVE PERFORMANCE AND LIFE SATISFACTION HAVE SHOWN TO RESULT FROM PARTICIPATION IN JUDO BY YOUNG PEOPLE.
收起
原文获取